KRAS and neoplasm: It is well known that the presence of KRAS and BRAF mutations in a patient’s tumor correlates strongly with resistance to anti-EGFR antibodies, and therefore, all patients are tested for BRAF and KRAS mutations before initiating anti-EGFR therapy [31].